CSL Ltd announced its half year
results to December, with net profit
after tax up 3% on the year before
period to US$646m.
This was on revenue of US$2.69b ,
up 5% on the previous period.
Its immunoglobulin product sales
grew 7% to US$1.09b in a global
market which remained “robust”,
the company said.
CSL ceo Paul Perreault said a new
drug the company was developing
to stop recurring heart attacks had
the potential to “transform our
business”, News.com.au reported.
The company was starting a Phase
IIb global clinical trial this year for
the drug, it said.The above article was sent to subscribers in Pharmacy Daily's issue from 14 Feb 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Feb 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.